Psychosis Research Study
Researchers at UC San Diego are conducting a study to evaluate the effects and long-term safety of an investigational treatment, Emraclidine, in adults with schizophrenia. This clinical trial aims to advance understanding and treatment of schizophrenia.
Fast Facts
Schizophrenia or a History of Psychosis
16-65 Years Old
Compensation Provided
Conducted in San Diego County and North County, CA
Study Background
Researchers at UC San Diego are conducting a study in adults to evaluate the effects, long-term safety, and tolerability of an investigational treatment for schizophrenia.
Schizophrenia is a chronic mental health condition that affects how individuals think, feel, and behave, often leading to symptoms like hallucinations, delusions, and difficulty with daily functioning. Current treatments primarily target symptoms but can come with side effects or limited effectiveness for some individuals. This study focuses on an investigational treatment called Emraclidine, which aims to improve the long-term safety and tolerability of schizophrenia treatments while addressing the condition’s core symptoms.
The findings of this study may contribute to developing more effective treatment options, improving outcomes, and enhancing the quality of life for individuals living with schizophrenia.
Study Background
Researchers at UC San Diego are conducting a study in adults to evaluate the effects, long-term safety, and tolerability of an investigational treatment for schizophrenia.
Schizophrenia is a chronic mental health condition that affects how individuals think, feel, and behave, often leading to symptoms like hallucinations, delusions, and difficulty with daily functioning. Current treatments primarily target symptoms but can come with side effects or limited effectiveness for some individuals. This study focuses on an investigational treatment called Emraclidine, which aims to improve the long-term safety and tolerability of schizophrenia treatments while addressing the condition’s core symptoms.
The findings of this study may contribute to developing more effective treatment options, improving outcomes, and enhancing the quality of life for individuals living with schizophrenia.
Additional Information
This study is being conducted to evaluate the effects, long-term safety, and tolerability of an investigational treatment called Emraclidine in adults with schizophrenia. The goal is to improve treatment options and enhance the quality of life for those living with this condition.
You or the person you are caring for may qualify if the following criteria is met:
Inclusion Criteria:
- Aged 16-65 years old
- Diagnosed with schizophrenia or experienced psychosis
- Willing to discontinue current antipsychotic medications before and during the trial
- Stable on schizophrenia medication for at least 3 months in the prior year
- Outpatient status at the time of screening
- Not pregnant or planning to become pregnant during the study
- BMI between 18 and 40
- Residing in a stable living environment
Exclusion Criteria:
- Pregnancy or planning pregnancy during the study
- Lifetime psychosis or bipolar disorder
- Serious neurological conditions (e.g., seizures, stroke, brain tumor)
- History of brain injury with loss of consciousness
- Traumatic brain injury requiring hospitalization
- MRI contraindications (e.g., claustrophobia, metal implants, weight over 300 lbs)
The entire study lasts up to 56 weeks, with a treatment duration of 52 weeks. Once enrolled, the study involves:
In the lab:
- 13 on-site visits where you’ll complete assessments of past and current psychiatric symptoms, physical assessments, ECG, a pregnancy test, blood draws, and urine tests.
- The first visit includes a detailed interview and questionnaire to assess your condition and eligibility.
From home:
- You’ll be asked to complete periodic check-ins regarding your health and treatment progress. These will involve phone calls or digital surveys that assess your experience during the trial.
Participants in this study will be compensated. You can receive up to $3,800 for completing the full 52-week trial. Additionally, you’ll be paid $200 per visit, plus any applicable incentives.
There is no cost for you to participate in our research study.
